Compare SNA & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNA | ILMN |
|---|---|---|
| Founded | 1920 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1B | 19.4B |
| IPO Year | 1994 | 2000 |
| Metric | SNA | ILMN |
|---|---|---|
| Price | $370.18 | $145.72 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 17 |
| Target Price | ★ $376.80 | $124.24 |
| AVG Volume (30 Days) | 376.3K | ★ 1.4M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | ★ 4.69 | 0.87 |
| Revenue | ★ $5,156,100,000.00 | $4,343,000,000.00 |
| Revenue This Year | N/A | $6.47 |
| Revenue Next Year | $3.66 | $5.58 |
| P/E Ratio | ★ $78.90 | $167.09 |
| Revenue Growth | ★ 0.93 | N/A |
| 52 Week Low | $304.90 | $78.80 |
| 52 Week High | $400.88 | $155.53 |
| Indicator | SNA | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 65.73 |
| Support Level | $358.04 | $116.54 |
| Resistance Level | $389.02 | $153.43 |
| Average True Range (ATR) | 10.63 | 5.76 |
| MACD | -1.59 | 1.40 |
| Stochastic Oscillator | 14.11 | 95.45 |
Snap-on is a manufacturer of premium tools, equipment, and diagnostics for professional technicians, primarily involved in the repair of passenger cars but having expanded into other industrial applications. The company's legacy business is selling hand tools through franchisee-operated mobile vans to technicians who purchase the tools at their own expense. The company also operates a commercial and industrial business that is focused on repair facilities serving other industries. The third segment, repair systems and information, targets auto OEMs and large dealerships more directly and also offers substantial diagnostic solutions to aid repairs. The company's finance arm provides financing to franchisees to run their operations, as well as underwriting end customer purchases.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.